Biotechnology News and Research

RSS

Unrestricted sales into prenatal health announced by Fluidigm

Fluidigm Corporation has announced that it can now offer unrestricted sales of its digital PCR and other advanced technology to customers interested in pursuing research and product development into the prenatal health and non-invasive prenatal diagnostics fields, as well as other fields.

28 May 2012

Major new research facility opens at Imperial College London

A major new research facility at Imperial College London designed to expand and accelerate the translation of scientific discoveries into new ways of preventing, diagnosing and treating diseases was officially opened by George Osborne MP, Chancellor of the Exchequer, today.

28 May 2012

Tβ4 offers both neurorestoration and neuroprotection after TBI

RegeneRx Biopharmaceuticals, Inc. reported that data showing that Thymosin beta 4 (Tβ4) "provides both neuroprotection and neurorestoration after traumatic brain injury (TBI)," was published in the current (May 2012) edition of the Journal of Neurosurgery, 116:1081-1092.

28 May 2012

ESRD patients with diabetes may benefit from Baxter’s low-glucose PD regimen

Baxter International Inc. today announced results from two large, international multicenter trials demonstrating that a low glucose peritoneal dialysis (PD) regimen favorably impacted metabolic measures important for end-stage renal disease (ESRD) patients with diabetes, including blood glucose (sugar) control and selected lipids.

From Baxter International Inc. 28 May 2012

FDA reauthorization bill sails through Senate

Showing unusual bipartisan spirit, the Senate passed a massive FDA user-fee reauthorization bill Thursday designed to prevent drug shortages and speed federal approval of medicines, including lower-cost generic versions.

25 May 2012

$CDC report finds states spend only a fraction of tobacco funds to fight smoking$

CDC report finds states spend only a fraction of tobacco funds to fight smoking

The study says states collected $244 billion from tobacco settlement payments between 1998 and 2010, and used about $8 billion of that for anti-smoking campaigns.

25 May 2012

BBSRC allocates £250M for strategic investment programmes

Minister for Universities and Science, David Willetts, will today announce substantial funding that will ensure the UK's bioscience research base remains globally competitive and at the forefront of meeting the grand challenges faced by society in the coming decades. The announcement will be made by the Minister during a visit to the Babraham Research Campus, near Cambridge, and highlighted again during a major speech at the University of East Anglia in Norwich.

25 May 2012

Cyanobacterium produces compounds that could treat chronic inflammatory conditions

A seaweed considered a threat to the healthy growth of coral reefs in Hawaii may possess the ability to produce substances that could one day treat human diseases, a new study led by scientists at Scripps Institution of Oceanography at UC San Diego has revealed.

25 May 2012

UCSF receives $20M Sandler Foundation gift for neuroscience research and care

UCSF has received a challenge gift of $20 million from the Sandler Foundation that will provide major support for the university's groundbreaking research and clinical care efforts regarding neurological diseases.

25 May 2012

Positive Results for Pulsar Stent in Clinical Study – BIOTRONIK announces

The six-month results from the prospective, multicenter, single-arm 4EVER study demonstrate efficacy and safety of BIOTRONIK's Pulsar Stent System in 120 superficial femoral artery (SFA) patients. Analysis of the 120 patients showed excellent device performance, very promising patency rates and convincing evidence of the benefits of lower limb intervention on a 4F platform. Although only the interim results were presented at the Leipzig Interventional Course (LINC 2012) in Leipzig, Germany, analysis of the full cohort has recently been made available.

24 May 2012

Brains that maintain healthy nerve connections as we age help keep us sharp in later life

Brains that maintain healthy nerve connections as we age help keep us sharp in later life, new research funded by the charity Age UK has found.

24 May 2012

Molecular Therapy releases characteristics and activity of SNS01 formulation

Senesco Technologies, Inc., announced today that the characteristics and activity of SNS01 have been released on-line in Molecular Therapy, the official journal of the American Society for Gene & Cell Therapy.

24 May 2012

Health Canada accepts Seattle Genetics’ ADCETRIS NDS for review

Seattle Genetics, Inc. announced today that the validation period is complete and Health Canada has accepted for review its New Drug Submission (NDS) for the use of ADCETRIS (brentuximab vedotin) in relapsed Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma.

24 May 2012

Zytoprotec completes PD-protec Phase I/II trial on kidney failure

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec.

24 May 2012

EMA accepts MAA filing of Takeda’s alogliptin for type 2 diabetes

Furiex Pharmaceuticals, Inc. today confirmed that Takeda Global Research & Development Centre (Europe) Ltd. received confirmation on the acceptance of the submission of a Marketing Authorization Application, or MAA, from the European Medicines Agency for alogliptin, a selective dipeptidyl peptidase IV, or DPP-4, inhibitor for the treatment of type 2 diabetes.

24 May 2012

Phase I/II clinical trial of novel dialysate completed by Zytoprotec

Zytoprotec, a company developing drugs based on active cytoprotection, today announced the completion of a Phase I/II clinical trial with its lead product, PD-protec™. The product is developed to improve the treatment of patients with kidney failure.

23 May 2012

HVTN opens enrollment in GeoVax’s GM-CSF adjuvanted vaccine Phase 1 trial for HIV

GeoVax Labs, Inc., an Atlanta-based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced that the NIH-funded HIV Vaccine Trials Network (HVTN) has opened enrollment for a Phase 1 trial for the company's second-generation HIV vaccine.

23 May 2012

“Sandwich” immunoassay used to search for new chemical reactions

Many discoveries are made by chance, but it is also possible to help it along: The chance of finding something interesting increases when the number of experiments rises. French researchers have now applied this principle to the search for new chemical reactions. In the journal Angewandte Chemie, they have introduced a new concept based on antibodies and a “sandwich” immunoassay.

22 May 2012

InterMune reaches definitive agreement with Vidara to sell Actimmune

InterMune, Inc. today announced that it has reached a definitive agreement with Vidara Therapeutics International Limited (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in a cash transaction valued at $55 million plus a two-year royalty stream.

22 May 2012

Opexa's Tovaxin for MS is now Tcelna

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), announced today that the Company is rebranding its leading MS therapy with the new name Tcelna. The product, previously known as Tovaxin, will now be known as Tcelna as the company positions itself towards the treatment of patients with Secondary Progressive MS (SPMS).

21 May 2012